Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2 ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® ...
Frontiers

Tissue‑immune crosstalk: Mechanisms and implications for T cell function and homeostasis

The field of tissue-immune interactions has undergone significant transformation as emerging evidence demonstrates the centrality of local microenvironments ...